Jump to main content
Jump to site search


Immunoconjugated up-conversion nanocomplex for selective imaging and photodynamic therapy against HER2-positive breast cancer

Abstract

Photodynamic therapy represents a very attractive therapeutic tool considered to be effective, minimally invasive and minimally toxic. However, conventional photodynamic therapy actually has two main constraints: the limited penetration depth of visible light needed for its activation, and the lack of selectivity. Considering that, this work reports the synthesis and evaluation of a novel nanoconjugate for imaging and selective photodynamic therapy against HER2-positive breast cancer, a particularly aggressive form of the disease. It was demonstrated that upon 975 nm near infrared light exposure, the red emission of the NaYF4:Yb,Er up-conversion nanoparticles (UCNPs) can be used for optical imaging and simultaneously represent the source for the excitation of a covalently bound zinc tetracarboxyphenoxy phthalocyanine (ZnPc), a photosensitizer that in turn transfer energy to ground state molecular oxygen to produce cytotoxic singlet oxygen. The specificity of our nanoconjugates was achieved by immunoconjugation with Trastuzumab (Tras), a specific monoclonal antibody for selective detection and treatment of HER2-overexpressing malignant breast cancer cells. Selective tracking of SKBR-3 HER2-positive cells was verified by confocal microscope analysis, and the photodynamic therapy effect was considerably improved when the Trastuzumab was incorporated to the nanoconjugate, being the UCNPs-ZnPc-Tras practically inert in absence of infrared light exposure but reducing the HER2-positive cell viability until 21% upon 5 min of the irradiation. This theranostic nanoconjugate represent a valuable alternative for HER2-positive breast cancer imaging and selective photodynamic therapy.

Back to tab navigation

Publication details

The article was received on 21 Feb 2018, accepted on 20 Apr 2018 and first published on 01 May 2018


Article type: Paper
DOI: 10.1039/C8NR01512K
Citation: Nanoscale, 2018, Accepted Manuscript
  •   Request permissions

    Immunoconjugated up-conversion nanocomplex for selective imaging and photodynamic therapy against HER2-positive breast cancer

    G. Ramírez García, S. S. Panikar, T. López-Luke, V. Piazza, M. A. Honorato Colin, T. Camacho Villegas, R. HERNÁNDEZ GUTIÉRREZ and E. De la Rosa-Cruz, Nanoscale, 2018, Accepted Manuscript , DOI: 10.1039/C8NR01512K

Search articles by author

Spotlight

Advertisements